-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

634A.O1.6 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Myelofibrosis: New Therapeutic Frontiers

Symposia: Myeloproliferative Syndromes: Clinical and Epidemiological Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, adult, MPN, Clinical Research, Combination therapy, Chronic Myeloid Malignancies, drug development, Diseases, Therapies, Myeloid Malignancies, Study Population, Human
Sunday, December 10, 2023: 4:30 PM-6:00 PM
Pacific Ballroom Salons 21-22 (Marriott Marquis San Diego Marina)
Moderators:
Firas El Chaer, MD, University of Virginia Comprehensive Cancer Center and Gabriela S. Hobbs, MD, Massachusetts General Hospital
Disclosures:
El Chaer: Bristol Myers Squib: Research Funding; Amgen: Consultancy, Research Funding; Celgene: Research Funding; Fibrogen: Research Funding; Sumitomo Pharma Oncology: Consultancy, Research Funding; Sanofi: Research Funding; PharmaEssentia: Research Funding; BioSight: Research Funding; MEI Pharma: Research Funding; Novartis: Research Funding; Arog Pharmaceuticals: Research Funding; Association of Community Cancer Centers: Consultancy; DAVA Oncology: Other: Travel grant; CTI Biopharma: Consultancy; AbbVie: Consultancy; MorphoSys: Consultancy. Hobbs: BMS: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees; Pharmaxis: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees; Regeneron: Current holder of stock options in a privately-held company; Morphosys: Membership on an entity's Board of Directors or advisory committees, Research Funding; Protagonist: Membership on an entity's Board of Directors or advisory committees; Keros: Membership on an entity's Board of Directors or advisory committees; Incyte: Research Funding; Novartis: Membership on an entity's Board of Directors or advisory committees.
As the therapeutic horizon broadens for myelofibrosis, this session focuses on the key clinical trials and emerging agents that are changing the landscape of this disease. Both early-phase and long-awaited later-phase trial data will be presented, as well as pivotal new data on disease transformation.
4:30 PM

Pankit Vachhani, MD1, Jana Baskar, MBBS, BMedSc2*, Brett Charlton, MD, PhD2*, Stanley Cheung, MD, PhD3*, Wolfgang Jarolimek, PhD2*, Sung-Eun Lee, MD4*, Peter Tan, MBBS (Hons), Mphil, FRACP, FRCPA5*, Anne Marie Watson, FRACP, FRCPA, MBBS6 and Shang-Ju Wu7*

1Roswell Park Comprehensive Cancer Center, Birmingham, AL
2Pharmaxis Ltd, FRENCHS FOREST, NSW, Australia
3ICON Cancer Care, Kurralta Park, Australia
4Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South)
5Royal Perth Hospital, Perth, Australia
6Liverpool Hospital SW Area Pathology Service, Liverpool, Nsw, AUS
7National Taiwan University Hospital, Taipei, Taiwan

4:45 PM

Lindsay A.M Rein, MD1, Firas El Chaer, MD2, Junichiro Yuda, MD, PhD3, Kazuya Shimoda, MD, PhD4, James McCloskey, MD5, Akiyoshi Takami, MD, PhD6, Tamanna Haque, MD7*, Michiko Ichii, MD, PhD8*, Shuichi Shirane, MD, PhD9*, Masafumi Fukaya, MD10*, Joseph M. Scandura, MD, PhD, MS11, Terrence Bradley, MD12, Pankit Vachhani, MD13, Takayuki Tabayashi, MD, PhD14*, Steven Green, MD15*, Stanley Cheung, MD, PhD16*, Prithviraj Bose, MD17, Sharad Khurana, MD, MSc18, Casey L. O'Connell, MD19, Idoroenyi Amanam, MD20, David M. Ross, MBBS, PhD, FRACP, FRCPA21*, Sujan Kabir, MD22*, Masataka Seki, MS23*, Mark Wade, PhD22*, Vishnu Peddagali, MD22*, Zhonggai Li, PhD22*, Jatin Shah, MD22 and Raajit K. Rampal, MD, PhD7

1Duke University, Durham, NC
2University of Virginia Health System, Charlottesville, VA
3National Cancer Center Hospital East, Kashiwa, Japan
4University of Miyazaki, Miyazaki, Japan
5The John Theurer Cancer Center at Hackensack Meridian Health, Hackensack, NJ
6Aichi Medical University School of Medicine, Nagakute, Japan
7Memorial Sloan Kettering Cancer Center, New York, NY
8Osaka University Graduate School of Medicine, Suita, Japan
9Juntendo University School of Medicine, Bunkyo-ku, Japan
10Shizuoka Cancer Center, Nagaizumi, Japan
11Weill Cornell Medical College, New York, NY
12University of Miami Sylvester Comprehensive Cancer Center, Miami, FL
13University of Alabama at Birmingham, Birmingham, AL
14Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
15Roswell Park Comprehensive Cancer Center, Buffalo, NY
16ICON Cancer Care, Kurralta Park, Australia
17MD Anderson Cancer Center, The University of Texas, Houston, TX
18University of Arizona Cancer Center, Tucson, AZ
19USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA
20City of Hope National Medical Center, Duarte, CA
21Royal Adelaide Hospital, Adelaide, SA, Australia
22Sumitomo Pharma America, Inc., Boston, MA
23Sumitomo Pharma Co., Ltd., Chuo-Ku, Japan

5:00 PM

Yu-Hung Wang, MD, MSc1,2*, Carmelo Gurnari, MD3, Chao-Hung Wei, MD4*, Hussein Awada3*, Chien-Chin Lin, MD, PhD5*, Andrius Zucenka, MD6,7, Chi-Yuan Yao, MD2*, Kristian Gurashi, PhD1*, Hsin-An Hou, MD, PhD2, Kiran Batta, PhD8, Wen-Chien Chou, MD, PhD9, Jaroslaw P. Maciejewski, M.D., Ph.D., FACP3, Daniel H Wiseman, MBBChir, FRCPath, MRCP, PhD10* and Hwei-Fang Tien, MD, PhD11

1The University of Manchester, Manchester, United Kingdom
2Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
3Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
4National Taiwan University Hospital, Taipei, Taiwan
5Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan
6Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania
7Hematology and Oncology Department, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
8Division of Cancer Sciences, The University of Manchester, Manchester, ENG, United Kingdom
9Department of Internal Medicine, Far-Eastern Memorial Hospital, New Taipei City, Taiwan
10Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom
11Department of Internal Medicine, Far-Eastern Memorial Hospital, New Taipei, Taiwan

5:15 PM

Raajit K. Rampal, MD, PhD1, Sebastian Grosicki, MD, PhD2*, Dominik Chraniuk3*, Elisabetta Abruzzese, MD4, Prithviraj Bose, MD5, Aaron T. Gerds, MD, MS6, Alessandro M. Vannucchi, MD7*, Francesca Palandri, MD8*, Sung-Eun Lee, MD9,10*, Vikas Gupta, MD11, Alessandro Lucchesi, MD12*, Stephen T. Oh, MD, PhD13, Andrew T. Kuykendall, MD14, Andrea Patriarca, MD15*, Alberto Alvarez-Larran, MD16*, Ruben A. Mesa, MD17, Jean-Jacques Kiladjian, MD, PhD18, Moshe Talpaz, MD19, Morgan Harris, PharmD20*, Sarah-Katharina Kays, PhD21*, Anna-Maria Jegg, PhD21*, Qing Li, PhD22*, Barbara Brown, PhD20*, Claire N Harrison23 and John Mascarenhas, MD24*

1Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY
2Department of Hematology and Cancer Prevention, Faculty of Health Sciences, Medical University of Silesia, Katowice, Poland
3Hematology Ward, Wojewodzki Szpital Zespolony im. L. Rydygiera, Torun, Poland
4Department of Hematology, S Eugenio Hospital, Tor Vergata University, Rome, Italy
5The University of Texas MD Anderson Cancer Center, Houston, TX
6Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
7Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy
8IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy
9Department of Hematology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South)
10Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South)
11Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
12Hematology Unit, IRCCS Istituto Romagnolo per lo Studio e la Cura dei Tumori (IRST) “Dino Amadori”, Meldola, Italy
13Washington University School of Medicine in St. Louis, St. Louis, MO
14Moffitt Cancer Center, Tampa, FL
15Hematology Unit, AOU Maggiore della Carità and University of Eastern Piedmont, Novara, Italy
16Hematology Department, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
17Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University School of Medicine, Winston-Salem, NC
18Clinical Investigation Center, Hôpital Saint-Louis, Université de Paris, Paris, France
19University of Michigan Comprehensive Cancer Center, Ann Arbor, MI
20Constellation Pharmaceuticals, a MorphoSys Company, Boston, MA
21MorphoSys AG, Planegg, Germany
22MorphoSys US Inc, Boston, MA
23Guy’s and St. Thomas’ NHS Foundation Trust, London, ENG, United Kingdom
24Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

5:30 PM

Rithin Nedumannil, MBBS, FRACP, FRCPA, MPH1*, Tal Karmi2*, Piers Blombery, MBBS2,3,4, Charlotte Hughes, MD, FRACP, FRCPA1*, Jeff Szer, MBBS, FRACP1,5, David S. Ritchie, MD, PhD, FRACP, FRCPA1,5 and Lynette C.Y. Chee, MBBS, PhD, FRACP, FRCPA1,5

1Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia
2Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
3Peter Maccallum Cancer Centre, East Melbourne, VIC, Australia
4Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia
5Department of Medicine, The University of Melbourne, Parkville, VIC, Australia

5:45 PM

Nico Gagelmann1*, Marie Quarder2*, Anita Badbaran3*, Christine Wolschke1*, Kristin Rathje4*, Mathias Schäfersküpper5*, Ameya Shrinivas Kunte, MD6, Evgeny Klyuchnikov7*, Radwan Massoud, BS, MD8*, Johanna Richter5*, Dietlinde Janson6*, Boris Fehse, PhD2*, Francis A. Ayuk, MD9* and Nicolaus Kroeger, MD1

1Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
2University Medical Center Hamburg-Eppendorf, Hamburg, DEU
3Department of stem cell transplantation, University Hospital Hamburg Eppendorf, Hamburg, DEU
4Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, AL, Germany
5University Medical Center Hamburg-Eppendorf, Hamburg, Germany
6Department of Stem Cell Transplantation, University Medical Center Hamburg Eppendorf, Hamburg, DEU
7Department of stem cell transplantation, University Cancer Center Hamburg-Eppendorf, Hamburg, Germany
8Department of Stem Cell Transplantation, University Medical Center Hamburg Eppendorf, Hamburg, Germany
9Department of Stem Cell Transplantation with Research Department Cell and Gene Therapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

*signifies non-member of ASH